Company
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUL 1, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for acyclovir oral suspension labeling; it documents a regulatory decision, not clinical evidence of efficacy or safety.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of oxycodone hydrochloride oral solution under REMS framework; regulatory action, not efficacy evidence.